PTO/SB/43 (07-09)
`Approved for use through 07/31/2012. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`
`Nameof Patentee
`Regeneron Pharmaceuticals, Inc.
`Patent Number
`11,253,572
`Title of Invention
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Docket Number (Optional)
`P35056US13/1106854.00017
`Date Patent Issued
`February 22, 2022
`
`| hereby disclaim the following complete claims in the above identified patent: 1-30
`
`
`The extent of myinterestin said patentis (if assignee of record, stateliber and page,or reel and frame, where
`assignmentis recorded): Assignee of record (reel/frame: 057417/0322)
`
`Thefeefor this disclaimeris set forth in 37 CFR 1.20(q).
`
`Patentee claims small entity status. See 37 CFR 1.27.
`
`Small entity status has already been established in this case, andis still proper.
`
`A checkin the amount of the fee is enclosed.
`
`Paymentby credit card. Form PTO-2038is attached.
`The Director is hereby authorized to charge anuiees which may be required or credit any
`overpayment to Deposit Account No. 50-238
`WARNING: Information onthis form may becomepublic. Credit card information should not
`be included on this form. Provide credit card information and authorization on PTO-2038.
`
`
`
`Tra
`
`
`
`Signature
`
`Underthe Paperwork Reduction Act of 1995, no personsare required to respondto a collection of information unless it displays a valid OMB control number. DISCLAIMER IN PATENT UNDER 37 CFR 1.321(a)
`
`Signed aTLARENstate otANEWYORK thislO aayor_IVEY 20TOUA),
`
`50,437
`Registration Number,if
`applicable
`
`Frank Cottingham
`
`VP, Associate General Counsel, Intellectual Property, Regeneron Pharmaceuticals, Inc.
`Typed orprinted nameof patentee/ attorney or agentof record
`
`914-847-1116
`Telephone Number
`
`777 Old Saw Mill River Road
`
`Address
`
`Tarrytown, NY 10591-6707
`City, State, Zip Code or Foreign Country as applicable
`
`
`
`netttttttttttttttt
`
`This collection of information is required by 37 CFR 1.321. The information is required to obtain or retain a benefit by the public which is to file (and by the
`USPTOto process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to
`complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case.
`Any comments on the amountof time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information
`Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR
`COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissionerfor Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`
`ifyou need assistance in completing the form,call 1-800-PTO-9199 and select option 2.
`
`

`

`Page 1 of 2
`P.O. Box 1450
`Alexandria, VA 22313 - 1450
`www.uspto.gov
`
`ELECTRONIC ACKNOWLEDGEMENT RECEIPT
`
`APPLICATION #
`17/352,892
`
`RECEIPT DATE / TIME
`07/10/2024 05:18:02 PM Z ET
`
`ATTORNEY DOCKET #
`P35056US13/1106854.00017
`
`Title of Invention
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Application Information
`
`APPLICATION TYPE Utility - Nonprovisional Application
`under 35 USC 111(a)
`
`PATENT #
`
`11253572
`
`FILED BY Sandra Tartisel
`
`FILING DATE 06/21/2021
`
`FIRST NAMED
`INVENTOR
`
`George YANCOPOULOS
`
`AUTHORIZED BY Alice Ho
`
`TOTAL DOCUMENTS: 1
`
`PAGES
`
`DESCRIPTION
`
`SIZE (KB)
`
`293 KB
`
`CONFIRMATION #
`
`5070
`
`PATENT CENTER #
`
`66312992
`
`CUSTOMER #
`
`191459
`
`CORRESPONDENCE
`ADDRESS
`
`-
`
`Documents
`
`DOCUMENT
`
`Disclaimer - P35056US13.pdf
`
`1
`
`Statutory disclaimers per
`Manual of Patent Examining
`Procedure(MPEP) 1490.
`
`Digest
`
`DOCUMENT
`
`MESSAGE DIGEST(SHA-512)
`
`Disclaimer - P35056US13.pdf
`
`8DC00BF59E9204F64FD8FE796BD92848B94E16F488D5F92EA
`81712D72400F8911C798A4DD314B143199C0C46EAF7B536562
`BE858B0C3078DA3B76F7E91090FA2
`
`

`

`Page 2 of 2
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized
`by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as
`described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d)
`and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement
`Receipt will establish the filing date of the application
`
`National Stage of an International Application under 35 U.S.C. 371
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.
`371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage
`submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for an
`international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the
`International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security,
`and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.
`
`

`

`Page 1 of 2
`P.O. Box 1450
`Alexandria, VA 22313 - 1450
`www.uspto.gov
`
`ELECTRONIC PAYMENT RECEIPT
`
`APPLICATION #
`17/352,892
`
`RECEIPT DATE / TIME
`07/10/2024 05:18:02 PM Z ET
`
`ATTORNEY DOCKET #
`P35056US13/1106854.00017
`
`Title of Invention
`USE OF A VEGF ANTAGONIST TO TREAT ANGIOGENIC EYE DISORDERS
`
`Application Information
`
`APPLICATION TYPE Utility - Nonprovisional Application
`under 35 USC 111(a)
`
`PATENT #
`
`11253572
`
`CONFIRMATION #
`
`5070
`
`PATENT CENTER #
`
`66312992
`
`CUSTOMER #
`
`191459
`
`CORRESPONDENCE
`ADDRESS
`
`-
`
`Payment Information
`
`FILED BY Sandra Tartisel
`
`AUTHORIZED BY Alice Ho
`
`FILING DATE 06/21/2021
`
`FIRST NAMED
`INVENTOR
`
`George YANCOPOULOS
`
`PAYMENT METHOD
`CARD / 0128
`
`PAYMENT TRANSACTION ID
`E202470H19066705
`
`PAYMENT AUTHORIZED BY
`Alice Ho
`
`FEE CODE
`
`DESCRIPTION
`
`ITEM PRICE($)
`
`QUANTITY
`
`ITEM TOTAL($)
`
`1814
`
`STATUTORY DISCLAIMER,
`INCLUDING TERMINAL DISCLAIMER
`
`170.00
`
`1
`
`170.00
`
`TOTAL
`AMOUNT:
`
`$170.00
`
`This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized
`by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as
`described in MPEP 503.
`
`New Applications Under 35 U.S.C. 111
`If a new application is being filed and the application includes the necessary components for filing date (see 37 CFR 1.53(b)-(d)
`and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement
`Receipt will establish the filing date of the application
`
`National Stage of an International Application under 35 U.S.C. 371
`
`

`

`Page 2 of 2
`
`If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C.
`371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage
`submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.
`
`New International Application Filed with the USPTO as a Receiving Office
`If a new international application is being filed and the international application includes the necessary components for an
`international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the
`International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security,
`and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.
`
`